These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. Willem C; Makanga DR; Guillaume T; Maniangou B; Legrand N; Gagne K; Peterlin P; Garnier A; Béné MC; Cesbron A; Le Bourgeois A; Chevallier P; Retière C J Immunol; 2019 Apr; 202(7):2141-2152. PubMed ID: 30787107 [TBL] [Abstract][Full Text] [Related]
43. Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone. Al-Homsi AS; Goodyke A; McLane M; Abdel-Mageed S; Cole K; Muilenburg M; Feng Y Biol Blood Marrow Transplant; 2017 Feb; 23(2):255-261. PubMed ID: 27888016 [TBL] [Abstract][Full Text] [Related]
44. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies. Sawada A; Shimizu M; Isaka K; Higuchi K; Mayumi A; Yoshimoto Y; Kikuchi H; Kondo O; Koyama-Sato M; Yasui M; Kawa K; Inoue M Pediatr Hematol Oncol; 2014 Nov; 31(8):754-64. PubMed ID: 25325678 [TBL] [Abstract][Full Text] [Related]
45. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Davies JK; Brennan LL; Wingard JR; Cogle CR; Kapoor N; Shah AJ; Dey BR; Spitzer TR; de Lima M; Cooper LJ; Thall PF; Champlin RE; Nadler LM; Guinan EC Clin Cancer Res; 2018 Sep; 24(17):4098-4109. PubMed ID: 29769208 [No Abstract] [Full Text] [Related]
46. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Im A; Rashidi A; Wang T; Hemmer M; MacMillan ML; Pidala J; Jagasia M; Pavletic S; Majhail NS; Weisdorf D; Abdel-Azim H; Agrawal V; Al-Homsi AS; Aljurf M; Askar M; Auletta JJ; Bashey A; Beitinjaneh A; Bhatt VR; Byrne M; Cahn JY; Cairo M; Castillo P; Cerny J; Chhabra S; Choe H; Ciurea S; Daly A; Perez MAD; Farhadfar N; Gadalla SM; Gale R; Ganguly S; Gergis U; Hanna R; Hematti P; Herzig R; Hildebrandt GC; Lad DP; Lee C; Lehmann L; Lekakis L; Kamble RT; Kharfan-Dabaja MA; Khandelwal P; Martino R; Murthy HS; Nishihori T; O'Brien TA; Olsson RF; Patel SS; Perales MA; Prestidge T; Qayed M; Romee R; Schoemans H; Seo S; Sharma A; Solh M; Strair R; Teshima T; Urbano-Ispizua A; Van der Poel M; Vij R; Wagner JL; William B; Wirk B; Yared JA; Spellman SR; Arora M; Hamilton BK Biol Blood Marrow Transplant; 2020 Aug; 26(8):1459-1468. PubMed ID: 32434056 [TBL] [Abstract][Full Text] [Related]
48. A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation. Riesner K; Kalupa M; Shi Y; Elezkurtaj S; Penack O Bone Marrow Transplant; 2016 Mar; 51(3):410-7. PubMed ID: 26595081 [TBL] [Abstract][Full Text] [Related]
49. Advances in haploidentical stem cell transplantation for hematologic malignancies. Montoro J; Sanz J; Sanz GF; Sanz MA Leuk Lymphoma; 2016 Aug; 57(8):1766-75. PubMed ID: 27424663 [TBL] [Abstract][Full Text] [Related]